IM 156

Drug Profile

IM 156

Alternative Names: IM156

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunoMet Therapeutics
  • Class Antineoplastics; Biguanides; Small molecules
  • Mechanism of Action AMP activated protein kinase inhibitors; Oxidative-phosphorylation-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Brain cancer; Diffuse large B cell lymphoma; Gastric cancer; Glioblastoma; Lung cancer

Most Recent Events

  • 03 Oct 2017 Phase-I clinical trials in Solid tumours (In the elderly, In adults, Late stage disease) in South Korea (NCT03272256)
  • 03 Oct 2017 Preclinical trials in Diffuse large B cell lymphoma in USA, prior to October 2017
  • 03 Oct 2017 Preclinical trials in Gastric cancer in USA, prior to October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top